They are talking about us!
Dear business relation,It is with a great enthusiasm that I share with you all our press release to the market officially announcing the completion of the acquisition of Movianto by the Walden group (new name of the entity EHDH).
The acquisition of Movianto fits perfectly into the vision and strategy that we have deployed for many years throughout our group, which is “to be a Pan European market leading player” in all markets that we play in. We set the standards and drive quality into the market.
Beyond the commercial benefits of this transaction, Movianto shares the same characteristics as our DNA: The foundations of a strong performing group who listens and cares for their clients.
The integration of Movianto, whose business and values we share, will allow us to gain critical size, strengthen our know-how and gain wider geographical footprint. The merger will allow us to respond favorably to our clients looking for a “one-stop-shop” solution for all their logistics needs on a European scale.
It was important to me to have this privileged communication with you and share the satisfaction that I have to take this step which, I am convinced, will allow us to further strengthen our relationships and the trust that binds us.
Should you need additional information, do not hesitate to reach out to your regular contact or myself.
Kind regards,
Andrea Siteur - CCO EHDH Benelux
T: +32 (0) 487 52 55 66 - E: asiteur@ehdh.fr
PRESS RELEASE WALDEN GROUP
Walden (ex-EHDH) finalizes the acquisition of Movianto and becomes the leading pharmaceutical logistics and transport player in Europe
Walden (formerly EHDH) announced today that it has completed the acquisition of Movianto, thereby becoming the European leader in transport and logistics services for the pharmaceutical sector. Stéphane Baudry, Chairman and CEO of Walden, is the majority shareholder of the new group. This acquisition is made on the basis of an enterprise value of 133 million US Dollars.
After Ciblex, Eurotranspharma, Eurodis and Ecocourses, the acquisition of Movianto marks a new essential milestone in the development of the family group founded in 1951 by the grandfather of current CEO Stéphane Baudry. 70 years after the creation of CSP and the first pharmaceutical pre-wholesaler warehouse in Clermont-Ferrand, the Walden group becomes the leading logistics and transport group in Europe.
The Walden group, born from the merger of EHDH and Movianto, currently has more than 5,000 employees spread over 625,000 m² of warehouses located in 12 European countries. Walden’s teams deliver nearly 500 000 packages a day with a quality that has made its reputation in a market where regulatory and health requirements make it one of the most specific to operate.
The Walden group will operate its services through its subsidiaries, the main brands of which are:
Concretely, this technological advance allows Walden to be the first player to provide its customers, within the same platform, with a one-stop service: real-time traceability throughout the supply chain, laboratory control quality, marketing authorizations, import and pharmaceutical release, customs broker, management of hospital calls for tenders, serialization, intelligent storage, “goods to man” process, scheduling, last miles deliveries, OPC invoicing … This new offer meets the needs and current trend of optimizing logistics processes and streamlining flows both with health entities (pharmacies, hospitals) but also directly to patients.
Should you need additional information, do not hesitate to reach out to your regular contact or myself.
Kind regards,
Andrea Siteur - CCO EHDH Benelux
T: +32 (0) 487 52 55 66 - E: asiteur@ehdh.fr
PRESS RELEASE WALDEN GROUP
Walden (formerly EHDH) announced today that it has completed the acquisition of Movianto, thereby becoming the European leader in transport and logistics services for the pharmaceutical sector. Stéphane Baudry, Chairman and CEO of Walden, is the majority shareholder of the new group. This acquisition is made on the basis of an enterprise value of 133 million US Dollars.
After Ciblex, Eurotranspharma, Eurodis and Ecocourses, the acquisition of Movianto marks a new essential milestone in the development of the family group founded in 1951 by the grandfather of current CEO Stéphane Baudry. 70 years after the creation of CSP and the first pharmaceutical pre-wholesaler warehouse in Clermont-Ferrand, the Walden group becomes the leading logistics and transport group in Europe.
The Walden group, born from the merger of EHDH and Movianto, currently has more than 5,000 employees spread over 625,000 m² of warehouses located in 12 European countries. Walden’s teams deliver nearly 500 000 packages a day with a quality that has made its reputation in a market where regulatory and health requirements make it one of the most specific to operate.
The Walden group will operate its services through its subsidiaries, the main brands of which are:
- Movianto, for logistics
- Eurotranspharma and Ciblex, for transport to pharmacies and hospitals
- Prima Transport, for upstream transport and fret forwarding
- Pharma Pilot, for IT solutions
Concretely, this technological advance allows Walden to be the first player to provide its customers, within the same platform, with a one-stop service: real-time traceability throughout the supply chain, laboratory control quality, marketing authorizations, import and pharmaceutical release, customs broker, management of hospital calls for tenders, serialization, intelligent storage, “goods to man” process, scheduling, last miles deliveries, OPC invoicing … This new offer meets the needs and current trend of optimizing logistics processes and streamlining flows both with health entities (pharmacies, hospitals) but also directly to patients.
This acquisition marks a major step in the development of the group that my grandfather founded 70 years ago: it is with honor and determination that I will carry out the integration of Movianto, which fits perfectly with our strategy of offering the best access solution to the European market for laboratories and health institutions. In a rapidly changing world, the challenges of the coming years lie in securing physical flows, particularly in sensitive industries with high added value. The tendency of laboratories to approach their end customers via “Direct To Patients” fits perfectly into our culture of always placing the customer at the center of our concerns.
STÉPHANE BAUDRY, CHAIRMAN OF WALDEN
